Abstract 5218
Background
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with rare driver gene alteration combinations in most men, requiring large sample sizes for stratified evaluations. We therefore hypothesized that the number of driver genes or pathways would affect prognosis in patients initiating androgen receptor signalling inhibitors (ARSi, i.e abiraterone acetate or enzalutamide).
Methods
We performed a post hoc analysis of the circulating tumor DNA (ctDNA) mutational landscape in ARSi-treated men with mCRPC (n = 342), recruited in our prospective, non-interventional, cohort study (n = 142) and the prospective NCT02125357 trial (n = 200). The driver gene mutational burden was defined as the number of detectable hotspot, pathogenic and/or function-affecting perturbations in 39 overlapping genes, which in turn were associated with 13 pathways. Progression-free survival (PFS) estimates were inferred by Kaplan-Meier analysis and multivariable Cox regression models, including the following covariates: PSA and ctDNA levels, prior chemotherapy, prior ARSi exposure, and presence of visceral metastases.
Results
Driver gene perturbations were detectedin 192/342 (56.1%) evaluable patients at baseline, with 152/192 (79.2%) and 40/192 (20.8%) perturbed patients having 1-3 and ≥ 4 significant events, respectively. PFS decreased as the driver mutational burden increased (0, 1-3, ≥ 4 drivers, median PFS 12.5 vs 5.6 vs 2.7 months, p < 0.0001). In multivariate analysis the driver burden reached significance once ≥ 4 driver hits were detected (HR 1.85, 95%CI 1.06-3.23, p = 0.03). The number of perturbed pathways reached independent prognostic value once ≥ 3 pathway or gene classes were affected (HR 1.7, 95%CI 1.02-2.84, p = 0.04). Additionally, in both models the presence of visceral metastases (p < 0.0001) and increasing PSA (p < 0.001) and plasma ctDNA (p < 0.001) levels were also independently associated with inferior outcome.
Conclusions
We demonstrate for the first time that the elevated driver mutational burden or number of affected pathways is independently associated with poor prognosis in mCRPC patients starting ARSi.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CORE-ARV-CTC and ProBio Investigators.
Funding
The Belgian Foundation Against Cancer, Kom op tegen Kanker (the Flemish Cancer Society), Royal College of Surgeons/Cancer Research UK, The Erling-Persson Family Foundation, the Swedish Research Council, and the Swedish Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3212 - Multigene panel testing results for hereditary breast cancer in 1325 individuals: implications for gene selection and considerations for guidelines.
Presenter: Georgios Tsaousis
Session: Poster Display session 3
Resources:
Abstract
2591 - PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Presenter: Julia Quintanilha
Session: Poster Display session 3
Resources:
Abstract
4377 - ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): a retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials.
Presenter: Nuria Chic
Session: Poster Display session 3
Resources:
Abstract
3439 - Early on-treatment vs pre-treatment tumor transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer
Presenter: Sonia Pernas
Session: Poster Display session 3
Resources:
Abstract
2512 - AXL expression predicts poor prognosis and lack of efficacy of anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC)
Presenter: Claudia Cardone
Session: Poster Display session 3
Resources:
Abstract
4061 - Prevalence of EGFR mutations and its correlation with Egyptian patients’ human kinetics (PEEK Study)
Presenter: Adel Ibrahim
Session: Poster Display session 3
Resources:
Abstract
2547 - Evaluation of tumor microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)
Presenter: Sergio Rutella
Session: Poster Display session 3
Resources:
Abstract
4671 - Clinicopathological and molecular criteria assessment for the screening of hypermutated proficient mismatch repair (pMMR) colorectal cancers (CRC) with exonucleasic domain POLE (edPOLE) mutations (mt).
Presenter: Benoit Rousseau
Session: Poster Display session 3
Resources:
Abstract
3862 - Tumor mutation burden and microsatellite instability in colorectal cancer
Presenter: Francesca Fenizia
Session: Poster Display session 3
Resources:
Abstract
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract